Compare GKOS & DAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | DAR |
|---|---|---|
| Founded | 1998 | 1882 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6B | 9.7B |
| IPO Year | 2015 | 2002 |
| Metric | GKOS | DAR |
|---|---|---|
| Price | $168.70 | $66.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 11 |
| Target Price | ★ $126.92 | $65.82 |
| AVG Volume (30 Days) | 573.4K | ★ 2.5M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.24 |
| Revenue | $507,442,000.00 | ★ $6,135,877,000.00 |
| Revenue This Year | $23.32 | $7.78 |
| Revenue Next Year | $27.43 | $3.37 |
| P/E Ratio | ★ N/A | $20.54 |
| Revenue Growth | ★ 32.33 | 7.36 |
| 52 Week Low | $73.16 | $29.15 |
| 52 Week High | $191.62 | $69.98 |
| Indicator | GKOS | DAR |
|---|---|---|
| Relative Strength Index (RSI) | 45.52 | 55.30 |
| Support Level | $96.44 | $57.88 |
| Resistance Level | $184.68 | $69.98 |
| Average True Range (ATR) | 6.22 | 2.49 |
| MACD | -2.25 | -0.14 |
| Stochastic Oscillator | 31.38 | 74.30 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Darling Ingredients Inc develops and produces sustainable natural ingredients from edible and inedible bio-nutrients for the pharmaceutical, food, pet food, animal feed, industrial, fuel, bioenergy, and fertilizer industries. The Company collects and processes animal by-products and recycled oils into ingredients. It operates through three reportable segments: Feed Ingredients, which generates maximum revenue and includes the collection and processing of animal by-products, used cooking oil, bakery residuals, pet food ingredients, hides, and fertilizers; Food Ingredients, which includes collagen, natural casings, and food-grade fats; and Fuel Ingredients, which includes renewable fuels, biogas, and energy products. The Company derives the majority of its revenue from North America.